AE

SetSail AI Pinpoints What Sales Reps Should Do to Win More

Retrieved on: 
星期三, 十一月 8, 2023

SAN MATEO, Calif., Nov. 8, 2023 /PRNewswire-PRWeb/ -- SetSail, the sales data platform that helps revenue teams do what wins, today enhanced its AI product to show reps the behaviors that increase win rates. Sales reps and leaders can also ask specific questions about deals to identify next best actions and close more deals.

Key Points: 
  • SetSail AI now analyzes activity data to find the specific rep behaviors that increase win rates and unstick stuck deals.
  • SAN MATEO, Calif., Nov. 8, 2023 /PRNewswire-PRWeb/ -- SetSail, the sales data platform that helps revenue teams do what wins, today enhanced its AI product to show reps the behaviors that increase win rates.
  • SetSail AI offers a new way for reps to see what they should be doing to hit their targets."
  • "SetSail AI offers a new way for reps to see what they should be doing to hit their targets.

Macrocell Radio/Active Antenna Unit Shipments Report 2023: Global Market and 5G Continues to Rely on China - Forecasts to 2027

Retrieved on: 
星期三, 十一月 8, 2023

DUBLIN , Nov. 8, 2023 /PRNewswire/ -- The "Global Macrocell Radio/Active Antenna Unit Market Analysis and Forecast - 2023-2027" report from EJL Wireless Research has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN , Nov. 8, 2023 /PRNewswire/ -- The "Global Macrocell Radio/Active Antenna Unit Market Analysis and Forecast - 2023-2027" report from EJL Wireless Research has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive analysis of the global radio unit (RU)/active antenna unit (AAU) market.
  • This report covers the global market share for 2022 shipments as well as a forecast for 2023-2027.
  • The analyst has segmented the overall market into three product segments types based upon the types of RU/AAU configurations such as Non-Massive MIMO, Massive MIMO, and Massive Antenna Element (AE).

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
星期三, 十一月 8, 2023

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Retrieved on: 
星期三, 十一月 8, 2023

BOSTON, Nov. 8, 2023 /PRNewswire/ -- ArisGlobal, creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology's ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications.

Key Points: 
  • A foundational and comparative study of ArisGlobal's LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives).
  • She commented: "Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug's addressable market.
  • "But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality.
  • ArisGlobal's CEO, Mike Gordon, commented, "Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring."

Global Macrocell Radio/Active Antenna Unit Market Report 2023: Market Share for 2022 Shipments and Forecasts 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
星期二, 十一月 7, 2023

The "Global Macrocell Radio/Active Antenna Unit Market Analysis and Forecast - 2023-2027" report from EJL Wireless Research has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Macrocell Radio/Active Antenna Unit Market Analysis and Forecast - 2023-2027" report from EJL Wireless Research has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive analysis of the global radio unit (RU)/active antenna unit (AAU) market.
  • This report covers the global market share for 2022 shipments as well as a forecast for 2023-2027.
  • The analyst has segmented the overall market into three product segments types based upon the types of RU/AAU configurations such as Non-Massive MIMO, Massive MIMO, and Massive Antenna Element (AE).

Sony Announces a9 III--World's First Global Shutter Mirrorless Camera and Sony's Lightest Super Telephoto Lens; First Look, Hands On YouTube Video Review at B&H Photo

Retrieved on: 
星期二, 十一月 7, 2023

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- B&H is excited to announce the Sony a9 III Mirrorless Camera, the world's first mirrorless camera with a global shutter sensor. They also revealed official details for the FE 300mm f/2.8 GM OSS Lens. This becomes the smallest super telephoto in the lineup and is the lightest in its class.

Key Points: 
  • Paired with BIONZ XR processing, the global shutter design enables recording full-resolution 14-bit raw stills at up to 120 fps.
  • The a9 III camera introduces Pre-Capture mode, which supports continuous shooting for up to 1 full second before capture by half-pressing the shutter button.
  • Beyond fast continuous shooting, the global shutter design, by nature, also enables flash sync at all shutter speeds, up to 1/80,000 sec.
  • And a variable shutter speed mode makes the a9 III's capture completely flicker free to suit photographing indoor activities at high speed.

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Retrieved on: 
星期一, 十一月 6, 2023

Updated data from the now completed dose escalation phase continue to showcase the manageable safety profile of 23ME-00610 at the dose levels tested, and highlight preliminary efficacy results in patients with advanced solid tumors.

Key Points: 
  • Updated data from the now completed dose escalation phase continue to showcase the manageable safety profile of 23ME-00610 at the dose levels tested, and highlight preliminary efficacy results in patients with advanced solid tumors.
  • The data was presented in two posters at the Society of Immunotherapy in Cancer Annual Meeting 2023 on Friday, November 3, 2023.
  • The poster presentations are available on the 23andMe Therapeutics and Investor websites.
  • Of the phase 1 patients enrolled across all doses of the dose escalation, there was a 52% stable disease rate.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
星期一, 十月 30, 2023

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

Retrieved on: 
星期一, 十一月 6, 2023

TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).
  • In data presented at AASLD’s The Liver Meeting®, TLC-2716 demonstrated highly potent and consistent improvements in plasma triglycerides and cholesterol and hepatic steatosis in preclinical models.
  • Notably, due to active hepatic uptake and limited systemic exposures, TLC-2716 did not adversely affect peripheral reverse cholesterol transport.
  • The results support the ongoing development of TLC-2716 in patients with metabolic disorders including SHTG and NASH.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
星期五, 十一月 3, 2023

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.